MX Orthopedics receives FDA clearance for compression staple

MX Orthopedics Corp. announced it has received FDA clearance for the dynaMX Compression Staple featuring malleable nitinol technology.

“MXO utilized its vast nitinol processing expertise to create the dynaMX Compression Staple,” Matthew Fonte, chief executive officer of MX Orthopedics (MXO), said in the press release.

Initially indicated for fracture and osteotomy fixation of the hand and foot, joint arthrodesis of the hand and foot, and fixation of proximal tibial metaphysis osteotomy, the compression staple combines super-elastic legs for compression with a malleable bridge, according to the press release. Surgeons can reportedly contour the device to match a patient’s anatomy for improved functionality and comfort. Other benefits of the compression staple include no post-insertion tamping required and easy intraoperative removal if needed.

The dynaMX Compression Staple is part of the company’s broader fracture fixation portfolio, which includes screws, plates and intramedullary implants.

“The dynaMX product line represents the next generation of fracture fixation and utilizes MXO’s metallurgical and engineering expertise, resulting in simple and intuitive implants that benefit patients,” Fonte said.

Reference:

www.mxortho.com/m%E1%BA%8D-orthopedics-receives-fda-clearance-on-the-dynam%E1%BA%8D-compression-staple-featuring-malleable-nitinol-technology